GB0607944D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0607944D0
GB0607944D0 GBGB0607944.6A GB0607944A GB0607944D0 GB 0607944 D0 GB0607944 D0 GB 0607944D0 GB 0607944 A GB0607944 A GB 0607944A GB 0607944 D0 GB0607944 D0 GB 0607944D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0607944.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0607944.6A priority Critical patent/GB0607944D0/en
Publication of GB0607944D0 publication Critical patent/GB0607944D0/en
Priority to US12/296,714 priority patent/US20090281126A1/en
Priority to CA002649648A priority patent/CA2649648A1/en
Priority to KR1020087025605A priority patent/KR20080110845A/ko
Priority to MX2008013520A priority patent/MX2008013520A/es
Priority to JP2009505894A priority patent/JP2009534358A/ja
Priority to PCT/EP2007/053847 priority patent/WO2007147659A1/en
Priority to AU2007263237A priority patent/AU2007263237B2/en
Priority to RU2008145708/04A priority patent/RU2008145708A/ru
Priority to BRPI0710514-2A priority patent/BRPI0710514A2/pt
Priority to CNA2007800142903A priority patent/CN101426785A/zh
Priority to EP07845239A priority patent/EP2013199A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
GBGB0607944.6A 2006-04-21 2006-04-21 Organic compounds Ceased GB0607944D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0607944.6A GB0607944D0 (en) 2006-04-21 2006-04-21 Organic compounds
EP07845239A EP2013199A1 (en) 2006-04-21 2007-04-19 Adenosine a3 receptor agonists
MX2008013520A MX2008013520A (es) 2006-04-21 2007-04-19 Agonistas del receptor de adenosina a3.
CA002649648A CA2649648A1 (en) 2006-04-21 2007-04-19 Adenosine a3 receptor agonists
KR1020087025605A KR20080110845A (ko) 2006-04-21 2007-04-19 아데노신 ａ3 수용체 작용물질
US12/296,714 US20090281126A1 (en) 2006-04-21 2007-04-19 Organic Compounds
JP2009505894A JP2009534358A (ja) 2006-04-21 2007-04-19 アデノシンａ３受容体アゴニスト
PCT/EP2007/053847 WO2007147659A1 (en) 2006-04-21 2007-04-19 Adenosine a3 receptor agonists
AU2007263237A AU2007263237B2 (en) 2006-04-21 2007-04-19 Adenosine A3 receptor agonists
RU2008145708/04A RU2008145708A (ru) 2006-04-21 2007-04-19 Агонисты аденозинового рецептора a3
BRPI0710514-2A BRPI0710514A2 (pt) 2006-04-21 2007-04-19 compostos orgánicos, seus usos e processos de preparação, e composições farmacêuticas compreendendo os mesmos
CNA2007800142903A CN101426785A (zh) 2006-04-21 2007-04-19 腺苷a3受体激动剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607944.6A GB0607944D0 (en) 2006-04-21 2006-04-21 Organic compounds

Publications (1)

Publication Number Publication Date
GB0607944D0 true GB0607944D0 (en) 2006-05-31

Family

ID=36581041

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0607944.6A Ceased GB0607944D0 (en) 2006-04-21 2006-04-21 Organic compounds

Country Status (12)

Country Link
US (1) US20090281126A1 (https=)
EP (1) EP2013199A1 (https=)
JP (1) JP2009534358A (https=)
KR (1) KR20080110845A (https=)
CN (1) CN101426785A (https=)
AU (1) AU2007263237B2 (https=)
BR (1) BRPI0710514A2 (https=)
CA (1) CA2649648A1 (https=)
GB (1) GB0607944D0 (https=)
MX (1) MX2008013520A (https=)
RU (1) RU2008145708A (https=)
WO (1) WO2007147659A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP2322525B1 (en) * 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EA000884B1 (ru) * 1996-01-02 2000-06-26 Рон-Пуленк Рорер Фармасьютикалз Инк. Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1383427A (zh) * 1998-12-31 2002-12-04 阿温蒂斯药物公司 制备n6－取代的脱氮杂一腺苷衍生物的方法
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
DE602004006895T2 (de) * 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
EP1778239B1 (en) * 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US7176172B2 (en) * 2004-10-25 2007-02-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Quaternary ammonium polyol salts as anti-aging actives in personal care compositions
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
RS52458B (sr) * 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori e1 aktivirajućih enzima
JP5339916B2 (ja) * 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
CN101410114B (zh) * 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
EA024006B1 (ru) * 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
EP2322525B1 (en) * 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CA2649648A1 (en) 2007-12-27
CN101426785A (zh) 2009-05-06
JP2009534358A (ja) 2009-09-24
EP2013199A1 (en) 2009-01-14
RU2008145708A (ru) 2010-05-27
KR20080110845A (ko) 2008-12-19
AU2007263237A1 (en) 2007-12-27
WO2007147659A1 (en) 2007-12-27
US20090281126A1 (en) 2009-11-12
BRPI0710514A2 (pt) 2011-08-16
MX2008013520A (es) 2008-10-29
AU2007263237B2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ZA200900263B (en) Organic compounds
GB0607948D0 (en) Organic compounds
GB0603684D0 (en) Organic compounds
GB0605691D0 (en) Organic Compounds
GB0606429D0 (en) Organic compounds
GB0605689D0 (en) Organic compounds
GB0607944D0 (en) Organic compounds
GB0605688D0 (en) Organic compounds
GB0605120D0 (en) Organic Compounds
GB0604937D0 (en) Organic compounds
GB0611463D0 (en) Organic compounds
GB0609378D0 (en) Organic compounds
GB0601406D0 (en) Organic Compounds
GB0601031D0 (en) Organic compounds
ZA200805331B (en) Organic compounds
GB0602123D0 (en) Organic compounds
GB0601951D0 (en) Organic compounds
GB0603782D0 (en) Organic compounds
GB0624814D0 (en) Organic compounds
GB0606562D0 (en) Organic compounds
GB0603880D0 (en) Organic compounds
GB0600238D0 (en) Organic compounds
GB0606202D0 (en) Organic compounds
GB0600618D0 (en) Organic compounds
GB0601405D0 (en) Organic Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)